Background: Enhanced production of endothelin-l (ET-I), vasoconstrictive 21 amino acids produced by endothelial cells during ischemia and after reperfusion of the liver, is known to cause sinusoidal constriction and microcirculatory disturbances, which lead to severe tissue damage. Using a 2-hour hepatic vascular exclusion model in dogs, we tested our hypothesis that neutralization of ET-l by monoclonal anti-ET-l and anti-ET-2 antibody (AwETN40) abates vascular dysfunction and ameliorates ischemia/reperfusion injury of the liver.
Endothelins (ETs), a group of vasoconstrictive 21 amino acids identified by Yanagisawa and colleagues (1), are involved in the pathogenesis of various disorders of the liver. They play regulatory roles in the hepatic microcirculation and exert glycogenolytic actions in the liver (2). In particular, ET-l, synthesized by sinusoidal cells and catabolized by hepatocytes (3), induces Ca 2 + release and stimulation of glycogen phosphorylase in hepatocytes (4) , constriction of Ito cells (5), and stimulation of platelet-activating factor in Kupffer cells (6) , More important, production of ET-1 is enhanced during ischemia and after reperfusion in the liver and causes sinusoidal constriction, leading to severe microcirculatory disturbances and tissue damage (7),
In this study. we examined the role of ET-1 in ischemia-induced liver damage in dogs by blocking its action with a novel anti-ET-l and anti-ET-2 monoclonal antibody, AwETN40, Methods A.nirn{/L~, . ,\dul t female beag-Ie dogs weighing--12 kg were used, This stud" was conducted with the approval of the Institutional Animal Care and Use Committee, and all animals were cared for according to 1'\ational Institutes of Health guidelines. After overnight !;lsting. the animals were anesthetized with thiopclltal sodium (25 mg/ kg) for inductioll, ;lnd ancsthesia was maintained with isotlurallt'. nitrous oxide, ;lnd oxygen bv positive pressure mechanical \'t'lltilalion. The right carotid ISS:\ 11l7~·7">l,)i'l7S17,()(} I'll Sllli:!·i.-)!"J('1i)(lllll:!')·:! arterY and right jugular vein were cannulated 101 monitoring arterial pressure and central \TIlOllS pressure and for obtaining blood samples. Electrocardiograph results and esophageal templ'ratllIT~ were monitored during the operatioll. Electrolvtl' solution (Plasmalvte. Travenol Laboratories. De'erfield. IL) was infu~ed (20 mL . kg -I ·h -I) throughout the operation to maintain adequate hydration and hemodynamic indices. Blood gases and electrolvtes were measured frequently and corrected if necessary.
Operative procedures. After entering the abdomen through a midline incision, we skeletonized the liver by dividing all of the suspensory hepatic ligaments. A venous catheter, Intracath 16GA (Becton Dickinson Vascular Access, Sandy, UT), was inserted into the suprahepatic inferior vena cava and positioned in the left hepatic vein for collecting hepatic venous blood samples. The catheter was tunneled beneath the skin and exteriorized between the scapulae to allow serial blood sampling after the operation. Total hepatic vascular exclusion was initiated by cross-clamping the portal vein, hepatic artery, and infra-and suprahepatic inferior vena cava. Pump-driven venavenous bypass (Biomedics, Minetonka, MN) was used to decompress the splanchnic venous bed and infrahepatic inferior vena cava (8) . The bypass circuit connected the left femoral vein and the splenic vein to the left jugular vein. The animals were given heparin (50 U/kg) 5 minutes before the initiation of ischemia. After 2 hours of ischemia, the liver was reperfused, the bypass system was removed, and a splenectomy was performed. Cefamandole nafate (1 g) was administered intraoperatively and continued for 3 postoperative days. The animals were allowed to eat and drink the morning after the operation and were followed for 2 weeks.
Experimental groups. AwETN40, a monoclonal anti-ET-l and anti-ET-2 antibody, was supplied by Takeda Chemical Industries Ltd. (Osaka, Japan). AwETN40 dissolved in saline was administered intravenously, at a dose of 5 mg/kg, 10 minutes before the initiation of ischemia (treatmen t group, n = 5). Animals receiving saline alone were used as controls (control group, n = 10).
Determinations. Two-week animal survival. liver function tests. total bile acid (TBA). hepatic tissue blood now (HTBF), tissue biochemistry. histopathology, and ET levels were used to e\'aluate the effican of the treatment in this stud\,. Peripheral \'enous blood samples were collected seriallv for determination of liver enzymes, including aspartate aminotransferase. alanine aminotransferase, L'rakami et al ISCIIE:-'UC UYER I:\.lL'RY 3:'>9 and lactate dehwlrogenase. In' a Techllicol1 RA:'>OO ~llltoal1alyzer (Baver. Tarn"towl1, 1\1'). Serum TBA \\'~IS measured hv the enzvmatic [1uorometric lIIethod using the Sterongnost-alpha Flu Kit (Nvegaad. Oslo. Norway) (9) . Serial measurements of IITBF were performed intraoperatively using a laser Doppler f10wmeter (Advance Laser Flowmeter. ALF21; Advance Company Ltd., Tokyo,Japan). The probe was placed on three lobes of the liver until a stable flow value was obtained. To avoid a misreading in HTBF measurements related to respiratory motion, the ventilation was always stopped briefly. The mean of these three values was used as the representative value and was expressed as a percentage of the value of the preischemia level.
Wedge liver biopsies collected before ischemia, at the end of ischemia, and 15 minutes and 60 minutes after reperfusion were diced into small pieces and immediately transferred into liquid nitrogen for the determination of adenine nucleotides. Concentrations of adenine nucleotides were measured using a Waters high-performance liquid chromatography system (Waters Chromatography Division/Millipore Corp. The other tissues were fixed in buffered formalin and stained with hematoxylin and eosin. Histopathology was examined by a single pathologist without knowledge of the groups or the timing of tissue sampling. Histologic assessment was performed semiquantitatively based on the degree of sinusoidal congestion, sinusoidal derangement, ischemic hepatocyte injury, and hepatocyte necrosis as follows: none = 0, mild = 1, moderate = 2, and severe = 3. The number of neutrophils infiltrated in the tissue was counted after Leder's staining (11) and expressed as that per 1,000 hepatocyte nuclei, Plasma concentration of imm unoreactive ET-l (irET-l) in the hepatic venous blood was measured by radioimmunoassav (12) . The 4-mL blood samples, collected in a Vacutainar 6452 tube (Becton Dickinson Vacutainer Systems, Rutherford, NJ) with 7.5 mg of ethvlenediamine tetraacetic acid, were centrifuged at 2.800 x g and 4°C for 10 minutes and were stored at -SO°C until the assay. Samples and standards (ET-l; Peninsula Laboratories, Belmont. CA.) were reconstituted in assav buffer and incubated for 24 hours with rabbit anti-ET-1 serum (RIK-6901; Peninsula Laboratories) at 4°C. The addition ofiodine125 ET-1 (Peninsula Laboratories) was followed by a second 24-hour incubation, and bound and free radio ligand were separated using the second antibody method. Sound radioactivity data were evaluated after logit/log transformation, and the irET-1 data were presented after correction for recovery. The rabbit antiserum exhibited a cross-reactivity of 17% with human big ET-1 and of 7% with ET-3, but no cross-reactivity with unrelated peptides (ie, atrial natriuretic peptide, brain natriuretic peptide, vasopressin, and angiotensins I, II, and III). and fell considerably immediately after reperfusion. Our operational procedure produced c.o.mplete liver ischemia, but there was false-posltlve tissue blood flow by Doppler flow measurement during ischemia, ranging from 8-11 ~ of the. preischemia levels (Fig. 2) . The restoratton of tlssue blood flow after reperfusion was significantly better in the treated animals than in the controls. Liver enz.yme levels. After reperfusion, levels of aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase were significantly lower in the AwETN40-treated animals than in control animals ( Fig. 3 ; Table 1 ).
Total bile acid. value at 6 hours after reperfusion and declined thereafter; levels in the control group continued to increase until 24 hours after reperfusion. Endothelin levels. Changes in irET-1 levels in the hepatic venous blood in the control group are shown in Figure 4 . Reperfusion of the liver after 2 hours of ischemia induced a significant rise in irET levels, by 4 times from 5 minutes to 60 minutes, 7 times at 3 hours, and> 18 times thereafter. Measurement of irET-1 in the treatment group failed because of the competitive nature of AwETN40 against the radioimmunoassay method used in this study.
Adenine nucleotides. Treatment 'with AwETN40 slowed the degradation of adenine nucleotides during ischemia and enhanced energy resynthesis after reperfusion (Table 2) . Adenosine triphosphate levels and total adenine nucleotide levels in the treatment group at 15 minutes and 60 minutes after reperfusion were significantly higher than those in the control group. Energy charge showed no significant difference between the groups.
Histology. Although no significant histologic differences were found at the end of 2-hour ischemia (irET-1 \ ill the hepatic \"(,1I0I1S bloud all1'1" reperillsiull. Itlrs <'7''!>I"l''' SE:-'I.'p "-.. lUI:) n'1'SWi P"'l'1·ltl'1lll( \;l1l1t':-*P ._ lUll '·,·1'slI.' prl'ischl'11l1c ,';lllll', and at 15 minutes after reperfusion, the treatment group showed significantly less structural damage and neutrophil infiltration in the liver than the control group. In particular, hepatocyte necrosis was not seen in any of the treatment-group animals (Table 3 ).
Discussion
In this study, we demonstrated that the neutralization of ET-1 by AwETN40 lessened microcirculatory disturbance, attenuated ischemia/reperfusion i~ury, and improved animal survival. In addition, pretreatment with AwETN40 slowed enzyme leakage, inhibited adenine nucleotide degradation in ischemic tissues, enhanced ATP resynthesis, and improved histopathologic findings.
Endothelins are a group of related 21-amino acid peptides (ET-1, ET-2, and ET-3) , which bind to three differen t types of ET receptors (ETA' ET B' and ETd (13) . In addition. two subtypes of ETB receptors have been identified. ET HI and ETl\~ (14) . ET\, has a high affinity for ET-1 and ET-2. but a low at1inity for ET-3. ETn has an equallv potent affinity for ET-l, -2, and -3 (15). The ET", receptor generally has been accepted as the predominant receptor subtype associated with vasoconstriction. The ETBI receptor is located in the endothelial cell and mediates vasodilation through the release of nitric oxide and prostacydin. The ETB~ receptor is located on the vascular smooth muscle cells and mediates vasoconstriction directlv (l()). In the liver. the number of these ET receptors per cdl is :~()-()O-fold higher on [to cells than on sinusoidal endothelial cells or hepatocvtes (17) . The abundance of ET receptors Oil Ito cells suggests that these cells are a major target for ET in the liver. Ito cells extend their numerous long cvtoplasmic processes to surround the sinusoidal wall and are involved in reducing the hepatic sinusoidal minocirculation bv contraction ( 1 R), .\mong variolls ETs. it has been shown that ET-! is a llIajor ET produced bv ischemia ;1I1d 362 J Al\1 COLL SCRG OCTOBER 1997 VOLUME 185:358 -364 reperfusion, and that both ETA and ET B receptors are located on the cell membrane ofIto cells (15) . Endothelin can be divided into two structural portions: (1) the N-terminal 15 amino acids, having a rigid structure with two disulfide bonds; and (2) the C-terminal heptapeptide, consisting of relatively hydrophobic amino acids. AwETN40 is a monoclonal antibody for ET-l and ET-2 that recognizes only the N terminal and not the C terminal. Although AwETN40 was first developed for the sandwich enzyme immunoassay for ET-l (19), it has also proved effective in preventing myocardial infarction (20) , acute renal failure (21), liver ischemia (22, 23), and endotoxin-induced liver injury (24) by its neutralizing activity against ET-l and ET-2.
The dosage of AwETN40 used in this experiment was based on previous reports. Watanabe and associates (20) showed that the effect of exogenous ET-l administration (0.75 mg/kg) on blood pressure was neutralized by pretreating animals with 1.5-4.5 mg/kg of AwETN40. They also found that the effect of 22.5 mg/kg AwETN40 lasted for > 24 hours. Using a I-hour partial (70%) liver ischemia model in dogs, Kawamura and colleagues (23) reported that pretreatment Table : ~. Histologic Findings with 2 mg/kg of AwETN40 was effective in attenuating ischemia/ reperfusion injury. Thus, we considered that the dosage of AwETN40 in this study, 5 mg/kg, would be sufficient for neutralization of ET-l in ischemia/reperfusion injury in the 2-hour total hepatic vascular exclusion model in dogs.
In this study, the concentration of irET-l in hepatic venous blood increased immediately after reperfusion and remained markedly elevated for up to 24 hours above 15.9 :t 7.1 pg/mL. Nakamura and associates (22) reported that irET-l increased to 12 pg/mL at 3 hours after reperfusion using a 60-minute total liver ischemia model in rats. Kawamura and colleagues (23) reported that irET-I increased to 6 pg/mL at 3 hours after reperfusion using the I-hour partial liver ischemia model in dogs. The different concentrations of irET-I between these studies may depend on the difference in species, the duration of ischemic time, the timing of the measurement, and the amount of ischemic liver damage. Levels of ET-l in the circulation after ischemia and reperfusion are influenced by the balance between production and its clearance by the il~ured liver. It has been demonstrated that hypoxia induces ET-I gene expression and secretion in endothelial cells (25) which is regulated by the degree of ischemia and the duration of reperfusion. In addition, interleukin-l, tumor necrosis factor, and transforming growth factor-l3, all of which are up-regulated by ischemia and reperfusion, stimulate ET-l production and release from sinusoidal endothelial cells (26) . Clearance of ET is markedly reduced in injured livers as compared with nonnalliyers (23). Exogenous ET-I has been shown to cause a pronounced elevation of intrahepatic vascular resistance, resulting in a profound decrease in hepatic blood flow and a refractory increase in portal pressure (2). In this study, although there was no difference in mean arterial pressure between the groups, preischemic administration of AwETN40 markedly improved HTBF after reperfusion. However, HTBF did not reach the preischemic level during the I-hour observation period, suggesting that the effect of this agent may not be sufficient or that there are other factors involved. First, AwETN40 barely moves from the bloodstream into the interstitial space because of its large molecular weight. It may bind easily to ET in the circulation, but it is more difficult to trap ET in the interstitial space, even if a sufficient dose of the agent is given intravenously. Second, ET-I exerts its action by an autocrine or paracrine mechanism. Ito cells have a very low level of ET-I mRNA in the normal liver, but it increases significantly once the liver receives ischemic insults (27) . In addition, when ET-I is produced by endothelial cells, 80% of the ET-I is released into the interstitial space rather than into the circulation (28) . Finally, insufficient restoration of HTBF in this stud~ may relate to other impaired endothelial cell functions, such as reduced svnthesis of nitric oxide and prostaglandins (29) .
The determination of serum TBA is a sensitive and specific index for hepatobiliary disorders that depends on the synthesis and excretory functions of hepatocvtes and the hepatic blood flow (30) . As shown in the present study, TBA increased immediately after reperfusion and remained high ill the control group for up to 24 hours; TilA levels in the treatment group began to decrease after 6 hours. indicating better hepatocyte function and greater hepatic blood flow.
.-\denosine triphosphate is the most hasic factor in mailllaining functional and structural ilHegritv of hepatoC\'tes t31 ). Reduction of ATP levels leads directl\' to the disturbance of cellular i11legritY and exacerbation of cellular dysfunctioll. Endothelin-l !OWCl'S A TP levels by increased consllmption (2) or inhibits ATP synthesis bv slIppressing the oxvgen suppl\" lhrollgh ';lSocollslrinioll (:t!L PrelreLltUrakami et al ISCHEMIC LIVER I:--:JURY 363 ment with AwETN40 abated these adverse effects of ET-I in this study.
The number of polymorphonuclear neutrophils (PMNs) infiltrated in postischemic liver tissue was significantly reduced by AwETN40 treatment. Polymorphonuclear neutrophils playa crucial role in the progression of ischemia/reperfusion injurv (33) . During interactions ofPMNs and ET-I, ET-I has been shown to stimulate migration and aggregation of PMNs (34) and to enhance superoxide anion production by the chemotactic peptide Nformyl-methionyl-Ieucyl-phenylalanine (35) . On the other hand, PMNs increase the induction of ET-I mRNA expression in endothelial cells (36) and convert big ET to ET-I (37). Furthermore, ET-I stimulates the expression of adhesive molecules, CDll/CD18 integrin, on the neutrophil surface (38). The expression of intercellular adhesion molecule-l and vascular cell adhesion molecule-Ion cerebromicrovascular endothelial cell lines is also up-regulated by ET-I (39). These observations suggest that ET-I exerts influence on PMNs by facilitating their adhesion to endothelial cells and infiltration into the tissue. Consequently, the neutralization of ET-I by AwETN40 appears, in part, to suppress PMNs' adhesion to endothelial cells, lessen PMNs' activation, and attenuate liver injury.
We postulated the following scenario on the basis of our findings. Two hours of ischemia causes extensive damage to sinusoidal endothelial cells in the liver. The damage triggers the production and release of endogenous ET-I that induces the constriction of Ito cells. leading to sinusoidal constriction and microcirculatory disturbances. The reduction in blood f10w augments postischemic tissue injury. In addition, ET-I enhances the various adverse actions of PMNs. The neutralization of ET-I by the monoclonal antibody AwETN40 is considered to contribute to the attenuation of liver damage bv inhibiting sinusoidal constriction and PMN action. which are involved in the pathogenesis of ischemia/ reperfusion injury of the liver.
